BPG is committed to discovery and dissemination of knowledge
This Article
  • Full Article (HTML) (54)
  • Full Article (PDF) (20)
Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (3901)
All Articles published online
The chart showing PDF series, HTML series, Scan QR Codes (HTML) series, Scan QR Codes (PDF) series, Figures (1-3) series, Tables (1-6) series.
Item 
Count 
PDF446
HTML3450
Scan QR Codes (HTML)54
Scan QR Codes (PDF)20
Figures (1-3)3
Tables (1-6)2
 Sum=3975
Jul 28, 2011 (publication date) through Jan 19, 2021
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef
Number Cited Articles
1
Kristian Aarslev, Anders Dige, Stinne R. Greisen, Martin Kreutzfeldt, Niels Jessen, Hendrik Vilstrup, Bent Deleuran, Henning Grønbæk. Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis. Scandinavian Journal of Gastroenterology 2017; 52(1): 93 doi: 10.1080/00365521.2016.1233576
2
Valli De Re, Maria Lina Tornesello, Mariangela De Zorzi, Laura Caggiari, Francesca Pezzuto, Patrizia Leone, Vito Racanelli, Gianfranco Lauletta, Laura Gragnani, Angela Buonadonna, Emanuela Vaccher, Anna Linda Zignego, Agostino Steffan, Franco M. Buonaguro. Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma. Frontiers in Microbiology 2019; 10 doi: 10.3389/fmicb.2019.00475
3
Cositha Santhakumar, Edward J. Gane, Ken Liu, Geoffrey W. McCaughan. Current perspectives on the tumor microenvironment in hepatocellular carcinoma. Hepatology International 2020; 14(6): 947 doi: 10.1007/s12072-020-10104-3
4
Mercedes Iñarrairaegui, Delia D’Avola, Bruno Sangro. Immunotherapy of Hepatocellular Carcinoma. 2017; : 51 doi: 10.1007/978-3-319-64958-0_4
5
Naofumi Mukaida, Yasunari Nakamoto. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma. World Journal of Gastroenterology 2018; 24(17): 1839-1858 doi: 10.3748/wjg.v24.i17.1839
6
Daniel S. Chen, Bryan A. Irving, F. Stephen Hodi. Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1. Clinical Cancer Research 2012; 18(24): 6580 doi: 10.1158/1078-0432.CCR-12-1362
7
Fabian Finkelmeier, Özge Canli, Andrea Tal, Thomas Pleli, Jörg Trojan, Michael Schmidt, Bernd Kronenberger, Stefan Zeuzem, Albrecht Piiper, Florian R. Greten, Oliver Waidmann. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. European Journal of Cancer 2016; 59: 152 doi: 10.1016/j.ejca.2016.03.002
8
Christopher E Jensen, Arturo Loaiza-Bonilla, Paula A Bonilla-Reyes. Immune checkpoint inhibitors for hepatocellular carcinoma. Hepatic Oncology 2016; 3(3): 201 doi: 10.2217/hep-2016-0004
9
Carolina Boni, Valeria Barili, Greta Acerbi, Marzia Rossi, Andrea Vecchi, Diletta Laccabue, Amalia Penna, Gabriele Missale, Carlo Ferrari, Paola Fisicaro. HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications. International Journal of Molecular Sciences 2019; 20(11): 2754 doi: 10.3390/ijms20112754
10
Colleen S. Curran, Elad Sharon. PD-1 immunobiology in autoimmune hepatitis and hepatocellular carcinoma. Seminars in Oncology 2017; 44(6): 428 doi: 10.1053/j.seminoncol.2017.12.001
11
Sophia Heinrich, Darko Castven, Peter R. Galle, Jens U. Marquardt. Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. Cancers 2020; 12(9): 2495 doi: 10.3390/cancers12092495
12
Mariko Ishibashi, Hiromi Yamaguchi, Yukari Hirotani, Akihisa Sakurada, Toshihide Endo, Masahiko Sugitani, Tadatoshi Takayama, Makoto Makishima, Mariko Esumi. Contradictory intrahepatic immune responses activated in high-load hepatitis C virus livers compared with low-load livers. Archives of Virology 2018; 163(4): 855 doi: 10.1007/s00705-017-3675-8
13
Cheng-Piao Luo, Han-Yue Mo, Ling-Ling Wu, Yun Ma, Ning-Fu Peng. Soluble PD-L1 and prognosis of patients with hepatocellular carcinoma. European Journal of Cancer 2017; 71: 117 doi: 10.1016/j.ejca.2016.09.040
14
Maridi Aerts, Daphné Benteyn, Hans Van Vlierberghe, Kris Thielemans, Hendrik Reynaert. Current status and perspectives of immune-based therapies for hepatocellular carcinoma. World Journal of Gastroenterology 2016; 22(1): 253-261 doi: 10.3748/wjg.v22.i1.253
15
Tim F. Greten, Firouzeh Korangy. Immunotherapy of Hepatocellular Carcinoma. 2017; : 121 doi: 10.1007/978-3-319-64958-0_8
16
Scott Balsitis, Volodymyr Gali, Pamela J. Mason, Susan Chaniewski, Steven M. Levine, Michael J. Wichroski, Michael Feulner, Yunling Song, Karen Granaldi, James K. Loy, Chris M. Thompson, Jacob A. Lesniak, Catherine Brockus, Narendra Kishnani, Stephan Menne, Mark I. Cockett, Renuka Iyer, Stephen W. Mason, Daniel J. Tenney, Isabelle Chemin. Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection. PLOS ONE 2018; 13(2): e0190058 doi: 10.1371/journal.pone.0190058
17
Daniel M. Girardi, Jana Priscila M. Pacífico, Fernanda P. L. Guedes de Amorim, Gustavo dos Santos Fernandes, Marcela C. Teixeira, Allan A. L. Pereira. Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives. Pharmaceuticals 2020; 14(1): 28 doi: 10.3390/ph14010028
18
Sarah Derks, Katie S. Nason, Xiaoyun Liao, Matthew D. Stachler, Kevin X. Liu, Jie Bin Liu, Ewa Sicinska, Michael S. Goldberg, Gordon J. Freeman, Scott J. Rodig, Jon M. Davison, Adam J. Bass. Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma. Cancer Immunology Research 2015; 3(10): 1123 doi: 10.1158/2326-6066.CIR-15-0046
19
Ming-fa Chen, Yong Lin, You-chen Xia, Chan Sun, Xue-mei Feng, Meng-ji Lu, Dong-liang Yang, Jun Wu. Establishment and application of hepatitis B virus persistent replication model in IFNAR−/− mouse. Journal of Huazhong University of Science and Technology [Medical Sciences] 2013; 33(3): 392 doi: 10.1007/s11596-013-1130-y
20
Weimin Zhu, Rui Bao, Xiaohua Fan, Tianzhu Tao, Jiali Zhu, Jiafeng Wang, Jinbao Li, Lulong Bo, Xiaoming Deng. PD-L1 Blockade Attenuated Sepsis-Induced Liver Injury in a Mouse Cecal Ligation and Puncture Model. Mediators of Inflammation 2013; 2013: 1 doi: 10.1155/2013/361501
21
Michael J. Flynn, Anwar A. Sayed, Rohini Sharma, Abdul Siddique, David J. Pinato. Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. Hepatology 2019; 69(5): 2258 doi: 10.1002/hep.30337
22
Elisabetta Cariani, Gabriele Missale. Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications. Liver International 2019; 39(9): 1608 doi: 10.1111/liv.14192
23
Changhoon Choi, Gyu Sang Yoo, Won Kyung Cho, Hee Chul Park. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World Journal of Gastroenterology 2019; 25(20): 2416-2429 doi: 10.3748/wjg.v25.i20.2416
24
Fanzhi Meng, Shoumei Zhen, Bin Song. HBV-specific CD4+ cytotoxic T cells in hepatocellular carcinoma are less cytolytic toward tumor cells and suppress CD8+ T cell-mediated antitumor immunity. APMIS 2017; 125(8): 743 doi: 10.1111/apm.12704
25
Noelle A. Hutchins, Fei Wang, Yvonne Wang, Chun-Shiang Chung, Alfred Ayala. Kupffer cells potentiate liver sinusoidal endothelial cell injury in sepsis by ligating programmed cell death ligand-1. Journal of Leukocyte Biology 2013; 94(5): 963 doi: 10.1189/jlb.0113051
26
Xianjing Li, Zhuo Wang, Yulian Zou, Ermei Lu, Jingjing Duan, Hongbao Yang, Qijin Wu, Xiaona Zhao, Yun Wang, Linjun You, Ling He, Tao Xi, Yong Yang. Pretreatment with lipopolysaccharide attenuates diethylnitrosamine-caused liver injury in mice via TLR4-dependent induction of Kupffer cell M2 polarization. Immunologic Research 2015; 62(2): 137 doi: 10.1007/s12026-015-8644-2
27
Sehar Afreen, Said Dermime. The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone. Hematology/Oncology and Stem Cell Therapy 2014; 7(1): 1 doi: 10.1016/j.hemonc.2013.09.005
28
Edoardo Giannini, Andrea Aglitti, Mauro Borzio, Martina Gambato, Maria Guarino, Massimo Iavarone, Quirino Lai, Giovanni Levi Sandri, Fabio Melandro, Filomena Morisco, Francesca Ponziani, Maria Rendina, Francesco Russo, Rodolfo Sacco, Mauro Viganò, Alessandro Vitale, Franco Trevisani. Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. Cancers 2019; 11(11): 1689 doi: 10.3390/cancers11111689
29
Tai Hato, Lipika Goyal, Tim F. Greten, Dan G. Duda, Andrew X. Zhu. Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions. Hepatology 2014; 60(5): 1776 doi: 10.1002/hep.27246
30
Omneya Y. Bassyoni, Heba M. Rashad. Expression of PD-1/PD-L1 and P53 in hepatocellular carcinoma. Egyptian Journal of Pathology 2018; 38(1): 131 doi: 10.1097/01.XEJ.0000542236.83764.02
31
Zuzana Macek Jilkova, Caroline Aspord, Keerthi Kurma, Anouck Granon, Christian Sengel, Nathalie Sturm, Patrice N. Marche, Thomas Decaens. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment. Clinical and Translational Gastroenterology 2019; 10(7): e00058 doi: 10.14309/ctg.0000000000000058
32
Stephen A. Locarnini, Michael Roggendorf. Viral Hepatitis. 2013; : 96 doi: 10.1002/9781118637272.ch7
33
Yaron Ilan. Immune therapy for hepatocellular carcinoma. Hepatology International 2014; 8(S2): 499 doi: 10.1007/s12072-013-9501-9
34
Michela Guardascione, Giuseppe Toffoli. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma. International Journal of Molecular Sciences 2020; 21(17): 6302 doi: 10.3390/ijms21176302
35
Yiyi Yan. The Basics of Cancer Immunotherapy. 2018; : 125 doi: 10.1007/978-3-319-70622-1_8
36
Zhu Li, Na Li, Fang Li, Zhihua Zhou, Jiao Sang, Yanping Chen, Qunying Han, Yi Lv, Zhengwen Liu. Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma. Medicine 2016; 95(52): e5749 doi: 10.1097/MD.0000000000005749
37
Hazel Lote, Catherine Cafferkey, Ian Chau. PD-1 and PD-L1 blockade in gastrointestinal malignancies. Cancer Treatment Reviews 2015; 41(10): 893 doi: 10.1016/j.ctrv.2015.09.004
38
Junsik Park, Minsuk Kwon, Eui-Cheol Shin. Immune checkpoint inhibitors for cancer treatment. Archives of Pharmacal Research 2016; 39(11): 1577 doi: 10.1007/s12272-016-0850-5
39
Hyung‑Wook Chun, Ran Hong. Significance of PD‑L1 clones and C‑MET expression in hepatocellular carcinoma. Oncology Letters 2019;  doi: 10.3892/ol.2019.10222
40
Zuzana Macek Jilkova, Caroline Aspord, Thomas Decaens. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. Cancers 2019; 11(10): 1554 doi: 10.3390/cancers11101554
41
G. Lin, W. Zhuang, X.H. Chen, C. Huang, X.D. Lin, Y.J. Huang, C. Li. Increase of programmed death ligand 1 in non-small-cell lung cancers with chronic hepatitis B. Annals of Oncology 2018; 29(2): 516 doi: 10.1093/annonc/mdx694
42
Oxana V. Makarova-Rusher, José Medina-Echeverz, Austin G. Duffy, Tim F. Greten. The yin and yang of evasion and immune activation in HCC. Journal of Hepatology 2015; 62(6): 1420 doi: 10.1016/j.jhep.2015.02.038
43
Valeria Barili, Carolina Boni, Marzia Rossi, Andrea Vecchi, Alessandra Zecca, Amalia Penna, Gabriele Missale, Carlo Ferrari, Paola Fisicaro. Metabolic regulation of the HBV-specific T cell function. Antiviral Research 2021; 185: 104989 doi: 10.1016/j.antiviral.2020.104989
44
Zongwen Shuai, Miranda WY Leung, Xiaosong He, Weici Zhang, Guoxiang Yang, Patrick SC Leung, M Eric Gershwin. Adaptive immunity in the liver. Cellular & Molecular Immunology 2016; 13(3): 354 doi: 10.1038/cmi.2016.4
45
Ziwei Li, Bin Li, Dan Peng, Haiyan Xing, Guanying Wang, Pan Li, Jiming Wang, George Ye, Jianhong Chen. Expression and clinical significance of PD‑1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PD‑1 monoclonal antibody. International Journal of Oncology 2018;  doi: 10.3892/ijo.2018.4358
46
Tim F. Greten, Bruno Sangro. Targets for immunotherapy of liver cancer. Journal of Hepatology 2018; 68(1): 157 doi: 10.1016/j.jhep.2017.09.007
47
Nobuhiro Tsuchiya, Yu Sawada, Itaru Endo, Yasushi Uemura, Tetsuya Nakatsura. Potentiality of immunotherapy against hepatocellular carcinoma. World Journal of Gastroenterology 2015; 21(36): 10314-10326 doi: 10.3748/wjg.v21.i36.10314
48
Antoine Hollebecque, David Malka, Charles Ferté, Michel Ducreux, Valérie Boige. Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons. European Journal of Cancer 2015; 51(3): 327 doi: 10.1016/j.ejca.2014.12.005
49
Michael A. Nalesnik. Hepatocellular Carcinoma. 2016; : 305 doi: 10.1007/978-3-319-34214-6_20
50
Christian Ihling, Bartholomew Naughton, Yue Zhang, P. Alexander Rolfe, Eveline Frick-Krieger, Luigi M. Terracciano, Isabelle Dussault. Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular Carcinoma. Frontiers in Medicine 2019; 6 doi: 10.3389/fmed.2019.00015
51
Ken Takahashi, Hiroyuki Marusawa. Molecular Diagnosis and Targeting for Thoracic and Gastrointestinal Malignancy. Current Human Cell Research and Applications 2018; : 93 doi: 10.1007/978-981-10-6469-2_6
52
Jin Yun, Genhua Yu, Pingping Hu, Yang Chao, Xingyu Li, Xiaobo Chen, Qichun Wei, Junfeng Wang. PD-1 expression is elevated in monocytes from hepatocellular carcinoma patients and contributes to CD8 T cell suppression. Immunologic Research 2020; 68(6): 436 doi: 10.1007/s12026-020-09155-3
53
Chiao-Fang Teng, Tsai-Chung Li, Ting Wang, Tzu-Hua Wu, John Wang, Han-Chieh Wu, Woei-Cherng Shyu, Ih-Jen Su, Long-Bin Jeng. <p>Increased Expression of Programmed Death Ligand 1 in Hepatocellular Carcinoma of Patients with Hepatitis B Virus Pre-S2 Mutant</p>. Journal of Hepatocellular Carcinoma 2020; : 385 doi: 10.2147/JHC.S282818
54
Wenfeng Fang, Shaodong Hong, Nan Chen, Xiaobo He, Jianhua Zhan, Tao Qin, Ting Zhou, Zhihuang Hu, Yuxiang Ma, Yuanyuan Zhao, Ying Tian, Yunpeng Yang, Cong Xue, Yanna Tang, Yan Huang, Hongyun Zhao, Li Zhang. PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival. Oncotarget 2015; 6(32): 33019 doi: 10.18632/oncotarget.5028
55
James J. Harding, Imane El Dika, Ghassan K. Abou-Alfa. Immunotherapy in hepatocellular carcinoma: Primed to make a difference?. Cancer 2016; 122(3): 367 doi: 10.1002/cncr.29769
56
Hae Il Jung, Dongjun Jeong, Sanghee Ji, Tae Sung Ahn, Sang Ho Bae, Susie Chin, Jun Chul Chung, Hyung Chul Kim, Moon Soo Lee, Moo-Jun Baek. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma. Cancer Research and Treatment 2017; 49(1): 246 doi: 10.4143/crt.2016.066
57
Smitha Menon, Sarah Shin, Grace Dy. Advances in Cancer Immunotherapy in Solid Tumors. Cancers 2016; 8(12): 106 doi: 10.3390/cancers8120106
58
Junyu Long, Jianzhen Lin, Anqiang Wang, Liangcai Wu, Yongchang Zheng, Xiaobo Yang, Xueshuai Wan, Haifeng Xu, Shuguang Chen, Haitao Zhao. PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. Journal of Hematology & Oncology 2017; 10(1) doi: 10.1186/s13045-017-0511-2
59
Bruno Sangro, Daniel Palmer, Ignacio Melero. Immunotherapy of hepatocellular carcinoma. Hepatic Oncology 2014; 1(4): 433 doi: 10.2217/hep.14.16
60
Won‐Mook Choi, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Young‐Suk Lim, Han Chu Lee, Young‐Hwa Chung, Young‐Sang Lee, Sook Ryun Park, Min‐Hee Ryu, Baek‐Yeol Ryoo, So Jung Lee, Kang Mo Kim. Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma. Hepatology Communications 2020; 4(7): 1073 doi: 10.1002/hep4.1523
61
Valli De Re, Maria Lina Tornesello, Mariangela De Zorzi, Laura Caggiari, Francesca Pezzuto, Patrizia Leone, Vito Racanelli, Gianfranco Lauletta, Stefania Zanussi, Ombretta Repetto, Laura Gragnani, Francesca Maria Rossi, Riccardo Dolcetti, Anna Linda Zignego, Franco M. Buonaguro, Agostino Steffan. PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus‐related diseases . Liver International 2021; 41(1): 133 doi: 10.1111/liv.14667
62
Edward N. Harris, Justin L. Mott. Molecules, Systems and Signaling in Liver Injury. 2017; : 1 doi: 10.1007/978-3-319-58106-4_1
63
Christo Kole, Nikolaos Charalampakis, Sergios Tsakatikas, Michail Vailas, Dimitrios Moris, Efthymios Gkotsis, Stylianos Kykalos, Michalis V. Karamouzis, Dimitrios Schizas. Immunotherapy for Hepatocellular Carcinoma: A 2021 Update. Cancers 2020; 12(10): 2859 doi: 10.3390/cancers12102859
64
Yingxin Han, Hongmei Li, Yanfang Guan, Jian Huang. Immune repertoire: A potential biomarker and therapeutic for hepatocellular carcinoma. Cancer Letters 2016; 379(2): 206 doi: 10.1016/j.canlet.2015.06.022
65
Wenfeng Fang, Jianwei Zhang, Shaodong Hong, Jianhua Zhan, Nan Chen, Tao Qin, Yanna Tang, Yaxiong Zhang, Shiyang Kang, Ting Zhou, Xuan Wu, Wenhua Liang, Zhihuang Hu, Yuxiang Ma, Yuanyuan Zhao, Ying Tian, Yunpeng Yang, Cong Xue, Yue Yan, Xue Hou, Peiyu Huang, Yan Huang, Hongyun Zhao, Li Zhang. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget 2014; 5(23): 12189 doi: 10.18632/oncotarget.2608
66
Mario Sznol, Lieping Chen. Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer. Clinical Cancer Research 2013; 19(5): 1021 doi: 10.1158/1078-0432.CCR-12-2063
67
Hao-Wen Sim, Jennifer Knox. Hepatocellular carcinoma in the era of immunotherapy. Current Problems in Cancer 2018; 42(1): 40 doi: 10.1016/j.currproblcancer.2017.10.007
68
Hui Li, Jun‐Quan Xia, Fang‐Shi Zhu, Zhao‐Hong Xi, Cheng‐Yu Pan, Li‐Mei Gu, Yao‐Zhou Tian. LPS promotes the expression of PD‐L1 in gastric cancer cells through NF‐κB activation. Journal of Cellular Biochemistry 2018; 119(12): 9997 doi: 10.1002/jcb.27329
69
Yu Akazawa, Toshihiro Suzuki, Toshiaki Yoshikawa, Shoichi Mizuno, Yasunari Nakamoto, Tetsuya Nakatsura. Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma. World Journal of Meta-Analysis 2019; 7(3): 80-95 doi: 10.13105/wjma.v7.i3.80
70
Elias A. Said, Iman Al-Reesi, Marwa Al-Riyami, Khalid Al-Naamani, Shadia Al-Sinawi, Mohammed S. Al-Balushi, Crystal Y. Koh, Juma Z. Al-Busaidi, Mohamed A. Idris, Ali A. Al-Jabri, Jean-Pierre Vartanian. Increased CD86 but Not CD80 and PD-L1 Expression on Liver CD68+ Cells during Chronic HBV Infection. PLOS ONE 2016; 11(6): e0158265 doi: 10.1371/journal.pone.0158265
71
Zhi-liang Wang, Guan-zhang Li, Qiang-wei Wang, Zhao-shi Bao, Zheng Wang, Chuan-bao Zhang, Tao Jiang. PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor. OncoImmunology 2019; 8(2): e1541535 doi: 10.1080/2162402X.2018.1541535
72
Lina Quan, Xue Chen, Aichun Liu, Yan Zhang, Xiuchen Guo, Shujie Yan, Yue Liu, Luwen Zhang. PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro. PLOS ONE 2015; 10(9): e0136476 doi: 10.1371/journal.pone.0136476
73
Koji Sawada, Hidemi Hayashi, Shunsuke Nakajima, Takumu Hasebe, Mikihiro Fujiya, Toshikatsu Okumura. Non‐alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor. Journal of Gastroenterology and Hepatology 2020; 35(6): 1042 doi: 10.1111/jgh.14889
74
Ryan M. Hickey, Laura M. Kulik, Halla Nimeiri, Aparna Kalyan, Sheetal Kircher, Kush Desai, Ahsun Riaz, Robert J. Lewandowski, Riad Salem. Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures. Journal of Vascular and Interventional Radiology 2017; 28(11): 1487 doi: 10.1016/j.jvir.2017.07.018
75
Hao Qiu, Liang Zheng, Weifeng Tang, Pengfei Yin, Feng Cheng, Lixin Wang. Programmed death-1 (PD-1) polymorphisms in Chinese patients with esophageal cancer. Clinical Biochemistry 2014; 47(7-8): 612 doi: 10.1016/j.clinbiochem.2013.12.023
76
Thomas C Wirth. Spontaneous and therapeutic immune responses in hepatocellular carcinoma: implications for current and future immunotherapies. Expert Review of Gastroenterology & Hepatology 2014; 8(1): 101 doi: 10.1586/17474124.2014.862497
77
A. J. Robert McGray, Jonathan Bramson. Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy. Advances in Experimental Medicine and Biology 2017; 1036: 213 doi: 10.1007/978-3-319-67577-0_14
78
Daniel L. Suzman, Lorraine Pelosof, Amy Rosenberg, Mark I. Avigan. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents. Liver International 2018; 38(6): 976 doi: 10.1111/liv.13746
79
Feng Gao, Yang Zhang, Li-Kun Wang, Yong-Li Wei, Jing-Wei Wang, Cheng-Bao Wang, Qiang Li. A Meta-Analysis of the Correlation Between the HLA-DRB1*03 Allele and Chronic Hepatitis B in the Han Chinese Population. Genetic Testing and Molecular Biomarkers 2015; 19(4): 218 doi: 10.1089/gtmb.2014.0096
80
Rong-Miao Zhou, Yan Li, Na Wang, Xi Huang, Shi-Ru Cao, Bao-En Shan. Association of programmed death-1 polymorphisms with the risk and prognosis of esophageal squamous cell carcinoma. Cancer Genetics 2016; 209(9): 365 doi: 10.1016/j.cancergen.2016.06.006
Write to the Help Desk
© 2004-2021 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345